References
- Paulson HL. The spinocerebellar ataxias. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2009;29(3):227–237.
- Ashizawa T, G Ö, Paulson HL. Spinocerebellar ataxias: prospects and challenges for therapy development. Nat Rev Neurol. 2018;14(10):590–605.
- Klinke I, Minnerop M, Schmitz-Hübsch T, et al. Neuropsychological features of patients with spinocerebellar ataxia (SCA) types 1, 2, 3, and 6. Cerebellum Lond Engl. 2010;9(3):433–442.
- Almeida-Silva UC, Hallak JEC, Júnior WM, et al. Association between spinocerebellar ataxias caused by glutamine expansion and psychiatric and neuropsychological signals - a literature review. Am J Neurodegener Dis. 2013;2(2):57–69. [cited 2021 Dec 2]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703120/
- Bird TD. Hereditary Ataxia Overview. In: Adam MP, Ardinger HH, and Pagon RA, et al., editors. GeneReviews®. eattle: University of Washington; 1993 1–17 . [cited 2021 Aug 17]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1138/
- Klockgether T, Mariotti C, Paulson HL. Spinocerebellar ataxia. Nat Rev Dis Primer. 2019;5(1):1–21.
- Soong BW, and Morrison PJ. Chapter 10 - Spinocerebellar ataxias. In: Manto M, and Huisman TAGM, editors. Handbook of Clinical Neurology. Vol. 155. The Cerebellum: Disorders and Treatment, Cambridge, MA: Elsevier; 2018. p. 143–174.
- Opal P, and Zoghbi H. The spinocerebellar ataxias. In: Eichler AF, editor. UpToDate. Waltham, MA: UpToDate; 2021. https://www.uptodate.com/contents/the-spinocerebellar-ataxias Accessed 17 Aug 2021
- Duenas AM. Molecular pathogenesis of spinocerebellar ataxias. Brain. 2006;129(6):1357–1370.
- Buijsen RAM, Toonen LJA, Gardiner SL, et al. Genetics, mechanisms, and therapeutic progress in polyglutamine spinocerebellar ataxias. Neurotherapeutics. 2019;16(2):263–286.
- Honti V, Vécsei L. Genetic and molecular aspects of spinocerebellar ataxias. Neuropsychiatr Dis Treat. 2005;1(2):125–133. [cited 2021 Dec 14]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2413192/
- Sullivan R, Yau WY, O’Connor E, et al. Spinocerebellar ataxia: an update. J Neurol. 2019;266(2):533–544.
- Bushart DD, Shakkottai VG. Ion channel dysfunction in cerebellar ataxia. Neurosci Lett. 2019;688:41–48.
- Chen ML, Lin CC, Rosenthal LS, et al. Rating scales and biomarkers for CAG-repeat spinocerebellar ataxias: implications for therapy development. J Neurol Sci. 2021;424:117417.
- Ristori G, Romano S, Visconti A, et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology. 2010;74(10):839–845.
- Romano S, Coarelli G, Marcotulli C, et al. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015;14(10):985–991.
- Shakkottai VG, Hua CC, Oddo S, et al. Ovid: enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. J Clin Invest. 2004;113(4):582–590. [cited 2021 Aug 8]. Available from: https://ovidsp-dc2-ovid-com.ezproxy.lib.usf.edu/ovid-a/ovidweb.cgi?Link+Set+Ref=00006114-201003090-00011|00004686_2004_113_582_shakkottai_neurodegeneration_%7c00006114-201003090-00011%23xpointer%28id%28R11-11%29%29%7c10%7c%7covftdb%7c00004686-200402040-00015&P=63&S=AHLJFPAPAJEBPOFFIPOJLGEHEAPBAA00&WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00006114-201003090-00011&Counter5=FTV_bibliographic%7c00004686-200402040-00015%7covft%7covftdb%7covftg
- Riluzole. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012. [cited 2021 Aug 17]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK548919/
- Biohaven Pharmaceuticals, Inc. A Phase III, Long-Term, Randomized, Double-Blind, Placebo-Controlled Trial of Troriluzole in Adult Subjects With Spinocerebellar Ataxia. clinicaltrials.gov; 2021. [cited 2021 Aug 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT03701399
- Bushart DD, Chopra R, Singh V, et al. Targeting potassium channels to treat cerebellar ataxia. Ann Clin Transl Neurol. 2018;5(3):297–314.
- Kasumu AW, Hougaard C, Rode F, et al. Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2. Chem Biol. 2012;19(10):1340–1353.
- Egorova PA, Zakharova OA, Vlasova OL, et al. In vivo analysis of cerebellar purkinje cell activity in SCA2 transgenic mouse model. J Neurophysiol. 2016;115(6):2840–2851.
- Shakkottai VG, Do Carmo Costa M, Dell’Orco JM, et al. Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. J Neurosci. 2011;31(36):13002–13014.
- Kasumu A, Bezprozvanny I. Deranged calcium signaling in purkinje cells and pathogenesis in spinocerebellar ataxia 2 (SCA2) and other ataxias. Cerebellum Lond Engl. 2012;11(3):630–639.
- Meera P, Pulst SM, Otis TS. Cellular and circuit mechanisms underlying spinocerebellar ataxias. J Physiol. 2016;594(16):4653–4660.
- Mark MD, Schwitalla JC, Groemmke M, et al. Keeping our calcium in balance to maintain our balance. Biochem Biophys Res Commun. 2017;483(4):1040–1050.
- Egorova PA, Bezprozvanny IB. Inositol 1,4,5-trisphosphate receptors and neurodegenerative disorders. FEBS J. 2018;285(19):3547–3565.
- Hisatsune C, Hamada K, Mikoshiba K. Ca2+ signaling and spinocerebellar ataxia. Biochim Biophys Acta Mol Cell Res. 2018;1865(11 Pt B):1733–1744.
- Shimobayashi E, Kapfhammer JP. Calcium signaling, PKC gamma, IP3R1 and CAR8 link spinocerebellar ataxias and purkinje cell dendritic development. Curr Neuropharmacol. 2018;16(2):151–159.
- Egorova PA, Bezprozvanny IB. Molecular mechanisms and therapeutics for spinocerebellar ataxia type 2. Neurother J Am Soc Exp Neurother. 2019;16(4):1050–1073.
- Prestori F, Moccia F, D’Angelo E. Disrupted calcium signaling in animal models of human spinocerebellar ataxia (SCA). Int J Mol Sci. 2019;21(1):216.
- Cho LTY, Alexandrou AJ, Torella R, et al. An intracellular allosteric modulator binding pocket in SK2 ion channels is shared by multiple chemotypes. Structure. 2018;26(4):533–544.e3.
- Bushart DD, Huang H, Man LJ, et al. A chlorzoxazone-baclofen combination improves cerebellar impairment in spinocerebellar ataxia type 1. Mov Disord. 2021;36(3):622–631.
- Fröhlich E, Wahl R. The forgotten effects of thyrotropin-releasing hormone: metabolic functions and medical applications. Front Neuroendocrinol. 2019;52:29–43.
- Sobue I, Takayanagi T, Nakanishi T, et al. Controlled trial of thyrotropin releasing hormone tartrate in ataxia of spinocerebellar degenerations. J Neurol Sci. 1983;61(2):235–248.
- Nishizawa M, Onodera O, Hirakawa A, et al. Effect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials. J Neurol Neurosurg Psychiatry. 2020;91(3):254–262.
- Zesiewicz TA, Wilmot G, Kuo SH, et al. Comprehensive systematic review summary: treatment of cerebellar motor dysfunction and ataxia. Neurology. 2018;90(10):464–471.
- Ijiro T, Yaguchi A, Yokoyama A, et al. Ameliorating effect of rovatirelin on the ataxia in rolling mouse Nagoya. Eur J Pharmacol. 2020;882:173271.
- Kimura N, Kumamoto T, Masuda T, et al. Evaluation of the effect of thyrotropin releasing hormone (TRH) on regional cerebral blood flow in spinocerebellar degeneration using 3DSRT. J Neurol Sci. 2009;281(1):93–98.
- Singh D, and Saadabadi A. Varenicline. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2021;1–7. [cited 2021 Aug 8]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK534846/
- Zesiewicz TA, Greenstein PE, Sullivan KL, et al. A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology. 2012;78(8):545–550.
- Ilg W, Bastian AJ, Boesch S, et al. Consensus paper: management of degenerative cerebellar disorders. The Cerebellum. 2014;13(2):248–268.
- Wecker L, Engberg M, Philpot R, et al. Neuronal nicotinic receptor agonists improve gait and balance in olivocerebellar ataxia. Neuropharmacology. 2013;73. DOI:https://doi.org/10.1016/j.neuropharm.2013.05.016.
- Loane C, Politis M. Buspirone: what is it all about? Brain Res. 2012;1461:111–118.
- Trouillas P, Xie J, Adeleine P. Treatment of cerebellar ataxia with buspirone: a double-blind study. Lancet. 1996;348(9029):759.
- Lou JS, Goldfarb L, McShane L, et al. Use of buspirone for treatment of cerebellar ataxia. An open-label study. Arch Neurol. 1995;52(10):982–988.
- Assadi M, Campellone JV, Janson CG, et al. Treatment of spinocerebellar ataxia with buspirone. J Neurol Sci. 2007;260(1–2):143–146.
- Lei LF, Yang GP, Wang JL, et al. Safety and efficacy of valproic acid treatment in SCA3/MJD patients. Parkinsonism Relat Disord. 2016;26:55–61.
- Gan SR, Wang J, Figueroa KP, et al. Postural tremor and ataxia progression in spinocerebellar ataxias. Tremor Hyperkinetic Mov N Y N. 2017;7:492.
- Lai RY, Tomishon D, Figueroa KP, et al. Tremor in the degenerative cerebellum: towards the understanding of brain circuitry for tremor. Cerebellum Lond Engl. 2019;18(3):519–526.
- Qi ZC, Ming HB, Ling HM, et al. Risk of valproic acid-related tremor: a systematic review and meta-analysis. Front Neurol. 2020;11:576579.
- Saute JAM, de Castilhos RM, Monte TL, et al. A randomized, phase 2 clinical trial of lithium carbonate in Machado-Joseph disease. Mov Disord Off J Mov Disord Soc. 2014;29(4):568–573.
- Saccà F, Puorro G, Brunetti A, et al. A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2. J Neurol. 2015;262(1):149–153.
- Schneider MA, Smith SS. Lithium-Induced neurotoxicity: a case study. J Neurosci Nurs J Am Assoc Neurosci Nurses. 2019;51(6):283–286.
- van de WBPC, van GJ, Boesch S, et al. EFNS/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood. Eur J Neurol. 2014;21(4):552–562.
- Botez MI, Botez-Marquard T, Elie R, et al. Amantadine hydrochloride treatment in heredodegenerative ataxias: a double blind study. J Neurol Neurosurg Psychiatry. 1996;61(3):259–264. [cited 2021 Aug 15]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC486548/
- Nissenkorn A, Hassin-Baer S, Lerman SF, et al. Movement disorder in ataxia-telangiectasia: treatment with amantadine sulfate. J Child Neurol. 2013;28(2):155–160.
- Pacheco LP, Thakur N Amantadine therapy for ataxia management in patients with spinocerebellar ataxia type 7. MDS Abstracts. [cited 2021 Aug 18]. Available from: https://www.mdsabstracts.org/abstract/amantadine-therapy-for-ataxia-management-in-patients-with-spinocerebellar-ataxia-type-7/
- Farzam K, and Abdullah M. Acetazolamide. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2021;1–5. [cited 2021 Nov 7]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK532282/
- Griggs RC, Moxley RT, Lafrance RA, et al. Hereditary paroxysmal ataxia: response to Acetazolamide. Neurology. 1978;28(12):1259–1264.
- Jen JC, Yue Q, Karrim J, et al. Spinocerebellar ataxia type 6 with positional vertigo and Acetazolamide responsive episodic ataxia. J Neurol Neurosurg Psychiatry. 1998;65(4):565–568.
- Yabe I, Sasaki H, Yamashita I, et al. Clinical trial of acetazolamide in SCA6, with assessment using the ataxia rating scale and body stabilometry: clinical trial of acetazolamide for SCA6. Acta Neurol Scand. 2001;104(1):44–47.
- Chen ZZ, Wang CM, Lee GC, et al. Trehalose attenuates the gait ataxia and gliosis of spinocerebellar ataxia type 17 mice. Neurochem Res. 2015;40(4):800–810.
- Chen YS, Hong ZX, Lin SZ, et al. Identifying therapeutic targets for spinocerebellar ataxia type 3/Machado–Joseph disease through integration of pathological biomarkers and therapeutic strategies. Int J Mol Sci. 2020;21(9):3063.
- Ltd BP. Bioblast announces phase 2a results of trehalose in patients with spinocerebellar ataxia type 3 (SCA3). GlobeNewswire News Room. Published January 18, 2017. [cited 2021 Nov 8]. Available from: https://www.globenewswire.com/news-release/2017/01/18/906630/32455/en/Bioblast-Announces-Phase-2a-Results-of-Trehalose-in-Patients-with-Spinocerebellar-Ataxia-Type-3-SCA3.html
- Noorasyikin MA, Azizan EA, Teh PC, et al. Oral trehalose maybe helpful for patients with spinocerebellar ataxia 3 and should be better evaluated. Parkinsonism Relat Disord. 2020;70:42–44.
- Miyai I, Ito M, Hattori N, et al. Cerebellar ataxia rehabilitation trial in degenerative cerebellar diseases. Neurorehabil Neural Repair. 2012;26(5):515–522.
- Bastian A, Keller JL. A home balance exercise program improves walking in people with cerebellar ataxia. Neurorehabil Neural Repair. 2014;28(8):770–778.
- Winser S, Smith C, Hale L, et al. Balance outcome measures in cerebellar ataxia: a Delphi survey. Disabil Rehabil. 2014;37. DOI:https://doi.org/10.3109/09638288.2014.913709
- Synofzik M, Ilg W. Motor training in degenerative spinocerebellar disease: ataxia-specific improvements by intensive physiotherapy and exergames. BioMed Res Int. 2014;2014:e583507.
- Grimaldi G, Argyropoulos GP, Boehringer A, et al. Non-invasive cerebellar stimulation—a consensus paper. Cerebellum. 2014;13(1):121–138.
- Commissioner O of the. FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive compulsive disorder. FDA. Published March 24, 2020. [cited 2021 Aug 15]. Available from: https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-transcranial-magnetic-stimulation-treatment-obsessive-compulsive-disorder
- Shiga Y, Tsuda T, Itoyama Y, et al. Transcranial magnetic stimulation alleviates truncal ataxia in spinocerebellar degeneration. J Neurol Neurosurg Psychiatry. 2002;72(1):124–126.
- Manor B, Greenstein PE, Davila-Perez P, et al. Repetitive transcranial magnetic stimulation in spinocerebellar ataxia: a pilot randomized controlled trial. Front Neurol. 2019;10:73.
- França C, de Andrade DC, Silva V, et al. Effects of cerebellar transcranial magnetic stimulation on ataxias: a randomized trial. Parkinsonism Relat Disord. 2020;80:1–6.
- Chen TX, Yang CY, Willson G, et al. The efficacy and safety of transcranial direct current stimulation for cerebellar ataxia: a systematic review and meta-analysis. Cerebellum Lond Engl. 2021;20(1):124–133.
- Pozzi NG, Minafra B, Zangaglia R, et al. Transcranial direct current stimulation (tDCS) of the cortical motor areas in three cases of cerebellar ataxia. Cerebellum. 2014;13(1):109–112.
- Benussi A, Koch G, Cotelli M, et al. Cerebellar transcranial direct current stimulation in patients with ataxia: a double-blind, randomized, sham-controlled study. Mov Disord Off J Mov Disord Soc. 2015;30(12):1701–1705.
- Benussi A, Dell’Era V, Cantoni V, et al. Cerebello-spinal tDCS in ataxia: a randomized, double-blind, sham-controlled, crossover trial. Neurology. 2018;91(12):e1090–e1101.
- Benussi A, Pascual-Leone A, Borroni B. Non-Invasive cerebellar stimulation in neurodegenerative ataxia: a literature review. Int J Mol Sci. 2020;21(6):1948.
- Hulst T, John L, Küper M, et al. Cerebellar patients do not benefit from cerebellar or M1 transcranial direct current stimulation during force-field reaching adaptation. J Neurophysiol. 2017;118(2):732–748.
- John L, Küper M, Hulst T, et al. Effects of transcranial direct current stimulation on grip force control in patients with cerebellar degeneration. Cerebellum Ataxias. 2017;4(1):15.
- Maas RPPWM, Toni I, Doorduin J, et al. Cerebellar transcranial direct current stimulation in spinocerebellar ataxia type 3 (SCA3-tDCS): rationale and protocol of a randomized, double-blind, sham-controlled study. BMC Neurol. 2019;19:149.
- Holeček M. Branched-chain amino acids in health and disease: metabolism, alterations in blood plasma, and as supplements. Nutr Metab. 2018;15(1):33.
- Mori M, Adachi Y, Mori N, et al. Double-blind crossover study of branched-chain amino acid therapy in patients with spinocerebellar degeneration. J Neurol Sci. 2002;195(2):149–152.
- Cooper JM, Korlipara LVP, Hart PE, et al. Coenzyme Q10 and vitamin E deficiency in Friedreich’s ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol. 2008;15(12):1371–1379.
- Lo RY, Figueroa KP, Pulst SM, et al. Coenzyme Q10 and spinocerebellar ataxias. Mov Disord Off J Mov Disord Soc. 2015;30(2):214–220.
- Lin CC, Ashizawa T, Kuo SH. Collaborative efforts for spinocerebellar ataxia research in the United States: CRC-SCA and READISCA. Front Neurol. 2020;11:902.
- Ouyang S, Xie Y, Xiong Z, et al. CRISPR/Cas9-Targeted deletion of polyglutamine in spinocerebellar ataxia type 3-derived induced pluripotent stem cells. Stem Cells Dev. 2018;27(11):756–770.
- Marthaler AG, Schmid B, Tubsuwan A, et al. Generation of an isogenic, gene-corrected control cell line of the spinocerebellar ataxia type 2 patient-derived iPSC line H196. Stem Cell Res. 2016;16(1):162–165.
- Marthaler AG, Schmid B, Tubsuwan A, et al. Generation of an isogenic, gene-corrected control cell line of the spinocerebellar ataxia type 2 patient-derived iPSC line H271. Stem Cell Res. 2016;16(1):180–183.
- Marthaler AG, Tubsuwan A, Schmid B, et al. Generation of an isogenic, gene-corrected control cell line of the spinocerebellar ataxia type 2 patient-derived iPSC line H266. Stem Cell Res. 2016;16(1):202–205.
- Babačić H, Mehta A, Merkel O, et al. CRISPR-cas gene-editing as plausible treatment of neuromuscular and nucleotide-repeat-expansion diseases: a systematic review. PLoS ONE. 2019;14(2):e0212198.
- Bennett CF, Krainer AR, Cleveland DW. Antisense oligonucleotide therapies for neurodegenerative diseases. Annu Rev Neurosci. 2019;42:385–406.
- Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, et al. Targeting huntingtin expression in patients with huntington’s disease. N Engl J Med. 2019 May 6; Published online. DOI:https://doi.org/10.1056/NEJMoa1900907.
- Scoles DR, Meera P, Schneider M, et al. Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature. 2017;544(7650):362–366.
- O’Callaghan B, Hofstra B, Handler HP, et al. Antisense oligonucleotide therapeutic approach for suppression of ataxin-1 expression: a safety assessment. Mol Ther Nucleic Acids. 2020;21:1006–1016.
- Moore L, Rajpal G, Dillingham I, et al. Evaluation of ASOs targeting ATXN3 in SCA3 mouse models. Mol Ther Nucleic Acids. 2017;7. DOI:https://doi.org/10.1016/j.omtn.2017.04.005.
- Niu C, Prakash TP, Kim A, et al. Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7. Sci Transl Med. 2018;10(465): eaap8677.
- Biogen. A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB105 Administered Intrathecally to Adults With Amyotrophic Lateral Sclerosis With or Without Poly-CAG Expansion in the Ataxin-2 Gene. clinicaltrials.gov; 2021. [cited 2021 Nov 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT04494256. *This is the first clinical trial to employ ASOs in the treatment of a neurodegenerative disease.
- Perez BA, Shutterly A, Chan YK, et al. Management of neuroinflammatory responses to AAV-Mediated gene therapies for neurodegenerative diseases. Brain Sci. 2020;10(2):119.
- Al-Zaidy SA, Kolb SJ, Lowes L, et al. AVXS-101 (Onasemnogene Abeparvovec) for SMA1: comparative study with a prospective natural history cohort. J Neuromuscul Dis. 2019;6(3):307–317.
- Schwartz M, Likhite S, Meyer K. Onasemnogene abeparvovec-xioi: a gene replacement strategy for the treatment of infants diagnosed with spinal muscular atrophy. Drugs Today Barc Spain 1998. 2021;57(6):387–399.
- Mendell JR, Al-Zaidy S, Shell R, et al. Single-Dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713–1722.
- Bushart DD, Murphy GG, Shakkottai VG. Precision medicine in spinocerebellar ataxias: treatment based on common mechanisms of disease. Ann Transl Med. 2016;4(2): 2-2.
- Massey TH, Jones L. The central role of DNA damage and repair in CAG repeat diseases. Dis Model Mech. 2018;11(1):dmm031930.
- Iyer RR, Pluciennik A. DNA mismatch repair and its role in huntington’s disease. J Huntingt Dis. 2021;10(1):75–94.
- Kacher R, Lejeune FX, and Noël S, et al. . In: Orr HT, Zoghbi HY, and Wheeler VC, editors. eLife. Vol. 10; 2021. p. e64674.
- Cancel G, Gourfinkel-An I, Stevanin G, et al. Somatic mosaicism of the CAG repeat expansion in spinocerebellar ataxia type 3/Machado-Joseph disease. Hum Mutat. 1998;11(1):23–27.
- Hübener-Schmid J, Kuhlbrodt K, Peladan J, et al. Polyglutamine-Expanded ataxin-3: a target engagement marker for spinocerebellar ataxia type 3 in peripheral blood. Mov Disord Off J Mov Disord Soc. 2021 Aug 16;36(11):2675–2681. Published online.
- Wilke C, Haas E, Reetz K, et al. Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. EMBO Mol Med. 2020;12(7):e11803.
- Adanyeguh IM, Perlbarg V, Henry PG, et al. Autosomal dominant cerebellar ataxias: imaging biomarkers with high effect sizes. NeuroImage Clin. 2018;19:858–867.
- Koscik TR, Sloat L, van der Plas E, et al. Brainstem and striatal volume changes are detectable in under 1 year and predict motor decline in spinocerebellar ataxia type 1. Brain Commun. 2020;2(2):fcaa184.